Phase 1 Myeloma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have given voluntary written consent to take part, with the understanding that they can withdraw at any time without it affecting their future care.
• People who are reasonably active and able to care for themselves, with a general health/activity score of 2 or below on a standard oncology scale (confirm with trial site).
• People aged 18 years or older.
• People who have measurable signs of multiple myeloma in their blood, urine, or through a specific protein level test (confirm with trial site for exact thresholds).
• People who have already been treated for multiple myeloma with at least three prior rounds of treatment, including specific types of drugs — an immunomodulatory drug, a proteasome inhibitor, and an anti-CD38 antibody — and whose myeloma has come back or stopped responding to treatment within 60 days of their last therapy.
• People whose blood cell and immune cell counts meet minimum required levels at the time of screening (confirm with trial site for exact values).
• People whose kidney function meets a minimum threshold, based on a standard kidney function calculation (confirm with trial site).
• People whose liver function test results are within acceptable ranges at screening (confirm with trial site).
• People who are able to take blood clot prevention medication, such as aspirin or a similar medicine.
• Women who could become pregnant must have two negative pregnancy tests before starting treatment and must agree to ongoing pregnancy testing and use of two reliable forms of contraception, or practise complete abstinence, throughout the trial and after it ends.
• Men must follow the trial's pregnancy prevention plan as outlined by the study team.
• People who agree to follow specific lifestyle guidelines during the trial, including rules around blood donation, staying near a hospital when required, and avoiding driving or operating heavy machinery when relevant.

Who may not be able to join:

• People who have received myeloma treatment or an experimental drug within the two weeks before starting the trial, or who are still experiencing side effects from a previous treatment.
• People who are currently taking part in another clinical trial involving an experimental drug.
• People who have previously been treated with mezigdomide or iberdomide.
• People who have previously received a type of treatment targeting a protein called GPRC5D (for example, talquetamab).
• People who have received a bispecific antibody therapy within the past three months.
• People who have received gene-modified cell therapy (such as CAR T-cells or NK cells) within the past three months.
• People who have had plasmapheresis (a procedure to filter the blood) within seven days before starting the trial.
• People whose myeloma never responded to any treatment from the very beginning (known as primary refractory disease).
• People who are currently taking high-dose steroid medications for their myeloma (low-dose steroids for unrelated conditions may be acceptable — confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.